RevOpsis Therapeutics, a San Carlos, CA-based biopharmaceutical company spearheading innovation in ophthalmic therapies, closed its first seed funding round, raising $16.5m.
The round of funding, which included $7.5m in non-dilutive capital, consisted of notable strategic investments including a contract development and manufacturing organization (CDMO) with global commercial drug supply capabilities, an ophthalmic drug and device development firm, and various private and angel investors, including several leading retina specialists.
The company intends to use the funds to complete the Investigational New Drug (IND) enabling studies to secure FDA authorization and conduct the first-in-human clinical trials with its lead candidate, RO-104 for the treatment of neovascular age-related macular degeneration (nAMD). This seed round will also support the ongoing discovery and development of RevOpsis’ pipeline, and allow the company to hire key management to drive the company forward.
Founded in 2018 by CEO Dr. Ram Bhandari, RevOpsis Therapeutics is a next-generation biopharmaceutical company spearheading innovation in ophthalmic therapies. RO-104 is a first-in-class modular tri-specific biologic curated to target all three dominant angiogenic pathways implicated in exudative retinal diseases. It has the potential to be the first monotherapy agent to improve visual outcomes and extend disease remission in patients suffering with nAMD.
FinSMEs
25/04/2024